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Abstract
Background: Onconase represents a new class of RNA-damaging drugs. Mechanistically, Onconase is thought to
internalize, where it degrades intracellular RNAs such as tRNA and double-stranded RNA, and thereby suppresses
protein synthesis. However, there may be additional or alternative mechanism(s) of action.
Methods: In this study, microarray analysis was used to compare gene expression profiles in untreated human
malignant mesothelioma (MM) cell lines and cells exposed to 5 μg/ml Onconase for 24 h. A total of 155 genes
were found to be regulated by Onconase that were common to both epithelial and biphasic MM cell lines. Some
of these genes are known to significantly affect apoptosis (IL-24, TNFAIP3), transcription (ATF3, DDIT3, MAFF,
HDAC9, SNAPC1) or inflammation and the immune response (IL-6, COX-2). RT-PCR analysis of selected up- or
down-regulated genes treated with varying doses and times of Onconase generally confirmed the expression array
findings in four MM cell lines.
Results: Onconase treatment consistently resulted in up-regulation of IL-24, previously shown to have tumor
suppressive activity, as well as ATF3 and IL-6. Induction of ATF3 and the pro-apoptotic factor IL-24 by Onconase
was highest in the two most responsive MM cell lines, as defined by DNA fragmentation analysis. In addition to
apoptosis, gene ontology analysis indicated that pathways impacted by Onconase include MAPK signaling,
cytokine-cytokine-receptor interactions, and Jak-STAT signaling.
Conclusions: These results provide a broad picture of gene activity after treatment with a drug that targets small
non-coding RNAs and contribute to our overall understanding of MM cell response to Onconase as a therapeutic
strategy. The findings provide insights regarding mechanisms that may contribute to the efficacy of this novel drug
in clinical trials of MM patients who have failed first line chemotherapy or radiation treatment.
Background
Onconase (ranpirnase), an extremely stable endoribonu-
clease that was originally isolated from the oocytes of
Rana pipiens,i sp a r to fap a r a d i g ms h i f ti nd r u gd e v e l -
opment. The intracellular target is RNA, not DNA or
protein. Onconase damage to tRNA [1-3] causes activa-
tion of the caspase cascade in mammalian cells and
results in apoptosis [2,4]. Although Onconase cleaves
tRNA at unique sites compared to other pancreatic type
RNases [5], inhibition of protein synthesis due to tRNA
damage cannot explain many activities of Onconase
[2,6]. Therefore, another postulated Onconase mechan-
ism is that it acts as an intracellular catalyst for the gen-
eration of interfering RNAs (RNAi) which could also
trigger apoptosis depending upon the microenvironment
of the cell [6]. Further information on the structure and
therapeutic potential of Onconase is found in several
recent reviews [7-9].
Therapeutic treatment of malignant mesothelioma
(MM) remains a major challenge. Prior studies have
shown that Onconase induces apoptosis in MM cells
and that this effect is tumor cell specific [10]. A
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inhibitors of phosphatidylinositol 3-kinase (PI3K) and
Onconase in the killing of MM cells. In MM cells with
increased PI3K activity, Rosiglitazone acted coopera-
tively with Onconase to inhibit cell proliferation [11].
Additional studies are needed to understand the action
of Onconase in MM cells. These studies may lead to
new combinatorial strategies that may enhance the
responsiveness of MM cells to treatment, given that in
other tumor types Onconase was shown to be strongly
synergistic when combined with other antitumor agents.
For example, the reduction of NF-B expression in
lymphocytic leukemia cells by Onconase appeared to be
associated with growth suppression, suggesting that NF-
B and its turnover are important determinants in the
anti-proliferative/apoptotic effects of Onconase in this
tumor cell context [12]. Also, a positive drug interaction
was shown between Onconase and Cepharanthine cyto-
toxicity when used in combination on various tumor
cell lines, and it was postulated that increased cytotoxi-
city may be associated with Onconase activity in target-
ing microRNAs and/or NF-B [13].
Preclinical work coupled with a novel mechanism led
to Phase I and Phase I/II clinical trials of Onconase as a
single therapeutic agent in patients with a variety of
solid tumors [14-16]. Currently, investigations have pro-
gressed to confirmatory Phase IIIb clinical trials for the
treatment of unresectable MM, one as a single agent
[17] and another in combination with doxorubicin. The
latter study included subjects with pleural and/or perito-
neal MM who had failed one prior systemic therapy,
and it was conducted at 27 centers in the U.S. and 31
centers outside the U.S. [18]. Although now closed to
enrolment, the FDA approval of premetrexed (Alimta) +
cisplatin as front-line treatment had an impact on the
type of subjects accrued to this trial and thus included a
sizeable population of subjects with previous chemother-
apy failure (total, N = 130; Onconase + doxorubicin, N
= 65; doxorubicin, N = 65). Hence, the statistical plan
provided for an analysis of outcomes based on prior
chemotherapy failure, and using this pre-specified com-
parison, subjects showed a clinically meaningful and sta-
tistically significant difference in overall survival
favouring the combination of Onconase + Doxorubicin
(hazard ratio 1.45; p = 0.033). The survival difference
was robust and the statistical significant effect was
maintained in a stratified Cox model (hazard ratio
1.548; p = 0.027) [18].
Since Onconase is in advanced clinical development, it
is even more important to understand the underlying
biological phenomenon connected with its mode of
action. Expression profiling is a useful approach to iden-
tify pathways altered upon exposure to drugs. Here, a
global transcriptional analysis using expression arrays
was used to simultaneously search thousands of genes
to delineate those that are differentially regulated by
Onconase in MM cells. We have identified a subset of
genes likely to be generally important in the response of
MM cells to Onconase, since they were common to cell
lines derived from both epithelial and biphasic tumors.
Elucidation of individual genes and their association
with signaling pathways should facilitate the develop-
ment of therapeutic strategies to improve the clinical
performance of Onconase.
Methods
Cell Lines, Reagents and Treatment
Human MM cell lines M25, M29, M35, M42 and M49
(kindly provided by S.C. Jhanwar [19]) were from pleural
tumors. Established cell lines (>passage 10) were propa-
gated in 10 cm dishes (Falcon) in RPMI medium con-
taining 10% FBS. M25 and M35 exhibited biphasic
characteristics, whereas M29, M42 and M49 were
epithelial in origin. Lyophilized Onconase, from Alfacell
Corporation, was dissolved in sterile distilled, deionized
water and prepared in medium (RPMI + 10% FBS).
Cell Viability Assay
An MTS assay (Promega CellTiter 96-AQueous One
Solution Assay) was used to analyze the effect of Onco-
nase on cell viability. Cells were cultured overnight in
96-well plates (~1 × 10
4 cells/well). Cell viability was
assessed after the addition of Onconase at the indicated
concentrations for 24, 48 or 72 h. The number of viable
cells was assessed by determination of the A490 nm of
the dissolved formazan product after addition of MTS
for 1 h as described by the manufacturer (Promega).
Expression Array Analysis
At ~50 to 80% confluence, all MM cell lines were incu-
bated with Onconase (5 μg/ml) for 24 h in the presence
of growth medium containing 10% fetal bovine serum.
The concentration and duration of the Onconase treat-
ment for the expression array were selected based on
our MTS results (Figure 1), in which there was ≤20%
loss of cell viability across most MM cell lines. Cells
were harvested, and total RNA was isolated with Trizol,
according to the manufacturer’s instructions (Invitro-
gen). Only RNA isolates that had an acceptable concen-
tration and absorbance 260/280 nm ratio from M25,
M29 and M49 cells were used.
Expression profiles were generated using Affymetrix
Human Genome U133 plus 2.0 Gene Chips (HG U133
plus 2.0) according to the Affymetrix Eukaryote One-
Cycle Target Labelling Assay. Briefly, 5 μg of total RNA
was used to synthesize double-stranded cDNA, which
was in vitro transcribed into biotinylated cRNA. The
biotinylated cRNA was fragmented and hybridized to
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dization Oven 640. Arrays were then washed and
stained on an Affymetrix Fluidics Station 450 using
Affymetrix fluidics protocol EukGE-WS2v5, and subse-
quently scanned on an Affymetrix GeneChip Scanner
3000 to obtain fluorescence intensities. Relative expres-
sion values were generated for each transcript using the
Affymetrix MAS5.0 algorithm in GeneChip® Operating
Software (GCOS) Version 1.4 with All Probe Sets Scal-
i n go f5 0 0 .D a t ah a v eb e e nd e p o s i t e di nN C B I ’sG e n e
Expression Omnibus repository http://www.ncbi.nih.gov/
geo/ and are available under the accession number
“GSE17009”.
Quantitative Real-Time PCR
M49 cells exhibited poor growth characteristics when
thawed from multiple frozen isolates and were not used
for further analysis. M25, M29, M35 and M42 were
used for quantitative real-time PCR. Following treatment
with Onconase, both adherent and floating cells were
collected and used for RNA isolation. Reverse transcrip-
tion of RNA to cDNA was performed using a High
Capacity cDNA Archive Kit (Applied Biosystems)
according to the manufacturer’s instructions. Reactions
for quantitative real-time PCR were prepared in a 25 μl
total volume with TaqMan® Universal PCR MasterMix
(Applied Biosystems), TaqMan® Gene Expression Assays
(Applied Biosystems) for PTGS2 (COX-2; assay ID:
Hs00153133_m1), IL-6 (assay ID: Hs00174131_m1), IL-
24 (assay ID: Hs01114274_m1), ATF3 (assay ID:
Hs00231069_m1), PTOV1 (assay ID: Hs00363189_g1) or
beta-2 microglobulin (assay ID: Hs99999907_m1) and
10-20 ng cDNA per the manufacturer’ss p e c i f i c a t i o n s .
Thermal cycling and detection of amplification products
were carried out on an ABI PRISM ® 7900 Sequence
Detection System (Applied Biosystems).
The average CT (threshold cycle) values for the target
genes and for beta-2 microglobulin were calculated from
the replicate values generated for each sample. The
average CT value for the housekeeping gene, beta-2
microglobulin, was subtracted from the average CT
value for each target gene in order to normalize values
for the amount of total cDNA added to the reaction.
Relative quantitation (i.e., fold-difference in expression
levels) between untreated and treated samples was cal-
culated using the Ct method (Applied Biosystems User
Bulletin Number 2).
DNA Fragmentation Assay
MM cells were treated with 5 μg/ml Onconase for 24,
48 and 72 h. Adherent and floating cells were collected
from untreated or treated cell cultures. Cells were lysed
and processed for DNA fragmentation using a Cell
Death Detection ELISA Kit (Roche Diagnostics) as per
the manufacturer’s instructions.
Gene Ontology Analysis
Gene names were entered into the GeneInfoVis pro-
gram [20]: http://genenet2.utmem.edu/geneinfoviz/
search.php. The resulting matching categories were
separated according to the Gene Ontology groupings
[21] based on the three broad ontology categories,
Figure 1 Human MM cells exhibit different sensitivities to Onconase. M25, M29, M35, M42, and M49 cells were plated at ~50% confluence,
treated with the indicated concentrations of Onconase and evaluated for cell viability by MTS assay at 0, 24, 48 and 72 h following treatment.
Graphs represent percent viability of Onconase-treated cells compared to corresponding untreated cells. Bars depict standard error among
replicate samples within a representative experiment. Results were validated in repeated experiments.
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gical process [P] and then counted. Onto-Express (OE,
[22]) was also used to identify those biological processes
that were impacted significantly by the Onconase regu-
lated genes (ORGs). Statistical significance values were
calculated for each category using either a hypergeo-
metric or binomial distribution depending on the num-
ber of genes on the array, as described elsewhere [22].
Assignment of Genes to Known Pathways
Two principal databases that assign proteins to path-
ways, KEGG [23] and BioCarta http://www.biocarta.com
were accessed through the Cancer Genome Anatomy
Project http://cgap.nci.nih.gov/Pathways/Pathway_-
Searcher. The KEGG and BioCarta resources provide a
reference knowledge base for linking genomes to biolo-
gical systems. The network representation of linkages
between ORGs and published pathways was constructed
and drawn using the program Cytoscape-2.6.0 available
online at http://www.cytoscape.org.
Results
Onconase inhibits MM cell viability
Similar to previous studies [10], cell viability assays
showed that some MM cell lines are more responsive to
Onconase than others. As expected, response was dose
and time dependent, with the greatest effect on cell via-
bility observed after 48 to 72 h (Figure 1). None of the
Onconase-treated cells reached an IC50 dose response
at the 24 h time point. As an unbiased approach to
examine gene expression in MM cells in response to
Onconase prior to a significant loss of viability, we
choose to analyze the 24 h time point across a panel of
cell lines that exhibited variable response to Onconase.
Subsequent studies validated that a subset of gene
expression changes were up-regulated in response to
Onconase in MM cell lines.
Onconase Regulated Genes (ORGs) common to three MM
cell lines detected by microarray-based expression
analysis
There is precedent for the use of microarrays to identify
specific genes that may be important in therapeutic
response of MM cells [24,25]. Here, the underlying mole-
cular mechanisms of Onconase-induced loss of MM cell
viability were investigated using expression array technol-
ogy. To select against individual cell line-specific
responses, we analyzed only ORGs common to three dif-
ferent MM cell lines. A comparison of the expression
profiles in the Onconase-treated and untreated cells
revealed 155 genes that were similarly up- of down-regu-
lated in all three cell lines. Most (66%) of the genes were
up-regulated (average increase from untreated cells ran-
ged from 1.2- to 14.6-fold), whereas 34% were down-
regulated (average decrease compared to untreated cells
ranging from 1.3- to 2.5-fold); this suggests that the pri-
mary effect of Onconase is activation of gene expression.
Many (52) of the genes were associated with one or more
cellular pathways. Potential ORGs common to the three
cell lines that increased an average of 3-fold or more
after Onconase treatment are shown in Table 1. Some of
these genes are known to significantly affect apoptosis
(IL-24 and TNFAIP3 p = 0.001), transcription (ATF3,
DDIT3, MAFF, HDAC9 and SNAPC1, p = 0.009) and
inflammation and the immune response (IL-6, p = 0.01
and COX-2, p = 0.001). Although none of the down-
regulated genes averaged a 3-fold decrease, PTOV1 was
decreased nearly 2-fold.
Quantitative real-time RT-PCR analysis of gene expression
Messenger RNA expression of four up-regulated genes
and one down-regulated gene were examined by quanti-
tative real-time RT-PCR in two of the three MM cell
lines used for the microarray analysis (M25 and M29)
plus two additional MM cell lines (M35 and M42) (Fig-
ure 2). All four cell lines were treated under conditions
identical to that used for the microarray analysis. ATF3,
IL-24 and IL-6 were among the most highly induced
genes detected in the array analysis (Table 1) and were
confirmed to be up-regulated by RT-PCR analysis in all
MM cell lines tested. COX-2, another up-regulated
gene, was validated to be increased in two of four MM
cell lines (Figure 2). PTOV1 expression was slightly
decreased or unchanged in the four cell lines. Quantita-
tive gene expression changes demonstrated a wide varia-
tion among the four individual cell lines but generally
were in the same direction as in the array analysis.
ATF3 expression increased from 3-fold to more than
400-fold, IL-24 from 2- to nearly 1000-fold, and IL-6
from 2- to nearly 100-fold. In comparison, COX-2
expression increased ~5 -fold in two cell lines and was
unchanged or decreased approximately 2-fold in one
line (Figure 2).
We also performed an expanded analysis of gene
expression in MM cells treated with Onconase at var-
ious doses (2.5 to 10 μg/ml), which showed highly
reproducible changes (Figure 3). Moreover, RT-PCR
performed on MM cell lines treated for varying times
(24 to 72 h) with 5 μg/ml Onconase showed remarkably
consistent up-regulated expression of IL-24 as well as of
ATF3 and IL-6 (Figure 4A). Among the five genes
tested, the gene encoding the pro-apoptotic factor IL-24
is noteworthy in that its expression increased with time
in three of four cell lines. Interestingly, induction of
ATF3 and IL-24 was highest in M35, a highly respon-
sive MM cell line, and lowest in M25, a poorly respon-
sive cell line, as defined by DNA fragmentation analysis
(Figure 4B).
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Although investigating individual gene expression can
provide insights about important aspects of Onconase
action, the overall mechanism is a heterogeneous phe-
nomenon that should also be defined by means of biolo-
gical processes and pathways. The entire group of ORGs
common to three MM cell lines was searched to identify
genes that could be characterized for a known ontology.
The resulting 155 gene name matches (hits) were used
to extract the associated ontologies based on three
broad ontology categories: the particular part of the cell
(cellular component); the activities of individual gene
products (molecular function); and their integration
with other genes to form a defined function (biological
process). Since each ORG could be associated with one
or more of these categories, the number of hits is listed
and not the number of genes (Additional file 1). The
major biological process ontologies (30 or more hits)
were related to cell signaling and signal transduction (34
hits), molecular events involving DNA (34 hits), and
transcription (60 hits). The individual function of the
ORGs favored metal ion binding and transcription and
Table 1 ORGs Up-regulated 3-fold or Greater
Probe Set
1 Name
1 Change
1 Gene Description
1 Biological Process
2
1560019_at DLGAP1 14.6 discs large (Drosophila) homolog-associated protein 1 cell-cell signaling
205749_at CYP1A1 10.8 cytochrome p 450 family 1 electron transport
drug metabolism
202672_s_at ATF3 9.4 activating transcription factor 3 transcription
209774_x_at CXCL2 8.6 chemokine (C-X-C motif) ligand 2 chemotaxis
206569_at IL-24 6.8 interleukin 24 apoptosis
205207_at IL-6 6.1 interleukin 6 acute phase response
B cell differentiation
cell cell signaling
cell surface linked signal transduction
humoral immune response
TNFAIP3 4.2 tumor necrosis factor, alpha induced protein 3 anti-apoptosis
apoptosis
negative regulation of transcription, DNA
dependent
204748_at PTGS2 (COX 2) 4.1 prostoglandin G/H synthase 2 cyclooxygenase activity
regulation of inflammatory response
209383_at DDIT3
(GADD153)
3.7 DNA-damage inducible transcripts 3 cell cycle arrest
transcription
regulation of transcription, DNA dependent
response to DNA damage stimulus
367_11 MAFF 3.5 v-maf parturition
regulation of transcription, DNA dependent
transcription from RNA polymerase II promoter
transcription
205659_ at HDAC9 3.2 histone deacetylase 9 B cell differentiation
histone deacetylation
inflammatory response
transcription
regulation of transcription, DNA dependent
202149_at NEDD9 3.0 neural precursor cell expressed developmentally actin filament bundle formation
cytoskeleton organization and biogenesis
205443_at SNAPC1 3.0 small nuclear RNA activating complex, polypeptide 1,
43 kDa
regulation of transcription, DNA dependent
transcription from RNA polymerase II promoter
transcription from RNA polymerase III promoter
transcription
1Affymetrix Data
2GeneInfoVis program [20,22]
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Methods. Error bars represent standard deviation in the expression level of ATF3, IL-24, IL-6, COX-2 and PTOV1 across three independent
experiments in MM cells treated with 5 μg/ml Onconase for 24 h.
Figure 3 Expanded series of quantitative RT-PCRs in MM cells treated with different concentrations of Onconase for 24 h. Human MM
cell lines M25, M29, M35, and M42 cells were treated with 0, 2.5, 5 and 10 μg/ml Onconase for 24 h, and RNA was isolated for real-time RT-PCR.
Error bars represent standard deviation in the expression level of ATF3, IL-24, IL6, COX-2 and PTOV1 using different dilutions of total RNA. Results
were validated in repeated experiments.
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(Additional file 1). Other significant biological processes
(15 or more hits) involved apoptosis, cell cycle, differen-
tiation/development, cell proliferation/growth, processes
involving RNA, metabolism/catabolism, transport and
protein molecular events such as phosphorylation,
assembly, binding and folding. Taken together, these
results (Additional file 1) show that ORGs participate in
important cellular events, mostly at the level of
transcription.
Signaling pathways affected by ORGs in MM cell lines
ORG expression was mapped to known metabolic and
regulatory pathways using two principal databases,
KEGG and BioCarta. To assign genes from the over- or
under-expressed gene probes, 155 usable names were
generated after removing duplicates and probes that did
n o tc o r r e s p o n dt oa n yk n o w ng e n e s .A m o n gt h e1 5 5
ORGs, there were 52 hits mapped to KEGG and/or Bio-
Carta Pathways. The data clearly show clusters of genes
in various pathways. Cell cycle and MAPK-associated
genes are two examples. Some of the genes (DUSP6, FAS,
HDAC9, IL-6, JAK1, JUN, PLCB4)a r el i n k e dt o1 0o r
more known pathways while others such as (CRY1, DIC1,
G T F 2 H 1 ,J A G 1 ,M A F F ,N P P B ,P B E F 1 ,P C L O ,Q P R T ,
RB1CC1, SAT, SIC2A3, SULT1A3, SUOX, TALDO1)a r e
only mapped to one. Overall, the data show that after 24
h of treatment, Onconase affects many of the genes
involved in classical pathways that control cell growth
and death. Some genes, for example CRY1,m a p p e dt o
unusual pathways such as circadian rhythm. While the
importance of this pathway to Onconase mechanism of
action is unknown, further research may link CRY1 to
other more obviously relevant pathways.
G e n e si n v o l v e di nM A P Ks i g n a l i n g( p=0 . 0 0 0 0 6 )a n d
cytokine-cytokine-receptor interaction (p = 0.006) were
Figure 4 Time course of expression changes and apoptosis induction in MM cells treated with 5 μg/ml Onconase. A. Bar graph
representative of quantitative RT-PCR expression changes. Human MM cell lines M25, M29, M35, and M42 cells were plated at ~50% confluence,
treated with 5 μg/ml Onconase for 0, 24, 48 and 72 h, and RNA was isolated. Error bars represent standard deviation in the expression level of
ATF3, IL-24, IL-6, COX-2 and PTOV1 using different concentrations of starting RNA. Results were validated in repeated experiments. Increased
levels of ATF3 and IL-24 were consistently observed at all time points. B. DNA fragmentation analysis of MM cells treated in parallel with samples
used for quantitative RT-PCR in “A”. M29 and M35 were most sensitive to apoptosis induced by 5 μg/ml Onconase at 48 or 72 h time points.
Enrichment of DNA fragmentation in Onconase-treated cells was determined by comparisons with untreated cells as per manufacturer’s
instructions. Error bars depict standard deviation between replicate fragmentation assays.
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involved are listed in Table 2 and depicted in Figure 5.
Jak-STAT (p = 0.06) signaling ORGs are also shown in
Table 2 and Figure 5. The p values of the other possible
pathway gene clusters ranged from p = 0.2 (Wnt signal-
ing) to p = 0.4 (cell cycle) to p = 0.9 (regulation of actin
cytoskeleton).
Interaction of ORGs in MM cell lines
In addition to Figure 5, Table 3 further illustrates the
interconnected relationship of ORGs and known path-
ways. More than half of the 35 shared pathways involve
signaling. One cluster (data not shown) contained
CYP1A1 and COX-2, two of the more highly up-regu-
lated ORGs (Table 1). CYP1A1 (tryptophan, linoleic and
fatty acid metabolism pathways) is connected via the
arachidonic acid metabolism pathway to COX-2 (eicosa-
noid metabolism pathway). The ORGs in the cytokine-
cytokine receptor and Jak-STAT pathways are directly
linked through shared genes, e.g. IL-6, IL-6st and IL-24.
Other relevant linkages are through second or third
order shared genes and pathways. For example, MAPK
to DUSP6 is linked further to the cytokine-cytokine
receptor pathways via TGFb signaling (Figure 5) and
INHBA. Numerous other linkages can also be seen.
Thus, Onconase-induced signals are propagated through
the cellular membrane and intracellular milieu. This
implies that Onconase initiates a cascade of ORG-
mediated responses leading to growth inhibition and
apoptosis in human MM cell lines.
Discussion
Microarray technology is a powerful tool for investigat-
ing cellular responses to drugs because it monitors
thousands of genes simultaneously. The present study is
the first to use microarray-derived transcriptional profil-
ing to identify ORGs common to multiple human MM
cell lines. Many ORGs are associated with cellular signal
transduction, proliferation and differentiation. Tran-
scription and DNA processes connected mainly with
membranes and the nucleus were the most affected
ontologies. All of this is consistent with the reprogram-
ming of cellular regulatory systems by Onconase. Impor-
tant new insights into Onconase mechanism include the
convergence of cellular responses to RNA damaging and
standard DNA-damaging drugs, and ORG interaction
with genes involved in MAPK signaling.
IL-24 was originally identified as mda-7, a gene selec-
tively up-regulated during terminal differentiation of
melanoma cells [26] and later classified as a member of
the IL-10 family [27]. Recently, an adenovirus encoding
the IL-24 gene has been shown to have selective antic-
ancer effects in cell culture and in animal models
(reviewed in [28]). IL-24 also sensitizes cells to radiation
and other conventional therapies, inhibits angiogenesis
and exhibits bystander effects in animal models. A repli-
cation-incompetent adenovirus encoding IL-24 (Ad.
mda-7) has undergone evaluation in a Phase I clinical
trial and showed rapid clinical advancement [28]. How-
ever, gene therapy protocols exhibit limitations asso-
ciated with local delivery and adverse immune reactions.
The specific high level induction of IL-24 by NSAIDs
has generated enthusiasm for increasing systemic levels
of IL-24 that might be effective without the limitations
of adenoviral delivery [29]. The present work shows that
Onconase also induces IL-24 mRNA in MM cells. This
finding has implications for understanding the basis for
the selective antitumor effects of Onconase in cell cul-
ture experiments [30] and its well tolerated activity in
patients [14]. Up-regulation of IL-24 might also be
related to the enhanced radiation sensitivity of non-
small cell lung cancer (NSCLC) cells treated with Onco-
nase [31], because IL-24 has been shown to sensitize
NSCLC xenograft tumors to radiation [32].
In view of these findings, combination therapy with
Onconase and NSAIDs should be considered in treating
MM patients if preclinical efficacy and safety studies
warrant it. NSAIDs decrease the expression of COX-2
and genes involved in the formation of inflammatory
prostaglandins from polyunsaturated fatty acids such as
arachidonic acid [33] in MM cells [34]. Thus, the use of
NSAIDS could moderate any potential effects of Onco-
nase on COX-2 expression, while the combined effect of
both agents might induce more IL-24 than either agent
alone. Indeed, an NSAID has been shown to increase
ectopic expression of IL-24 that augmented adenovirus
delivery leading to the proposed use of more than one
inducer of IL-24 to achieve superphysiological levels of
this pro-apoptotic factor in tumors [35].
ATF3 has not previously been associated with Onco-
nase activity. ATF3 (activating transcription factor 3), a
member of the ATF/CREB family of transcription fac-
tors, participates in cellular processes to adapt to extra/
intracellular changes [36]. It is expressed at low levels in
normal and quiescent cells but can be induced by a vari-
ety of extracellular agents, including radiation [37] and
other genotoxic stress signals [38]. The consequences of
ATF3 induction result in tumor growth inhibition and
suppression of Ras-stimulated tumorigenesis [37,38].
ATF3 mRNA was up-regulated in MM cell lines used in
the microarray expression analysis as well as in two
additional human MM cell lines examined, indicating
that the Onconase up-regulation of ATF3 is not cell line
specific.
Chemotherapeutic agents that damage DNA also
induce ATF3. Camptothecin and etoposide, DNA topoi-
somerase inhibitors [39], as well as the anthracycline
antibiotic doxorubicin [40] have all been shown to
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fected ATF3 accelerated drug-induced apoptosis [39]. 5-
Fluorouracil (5-FU) is used in the treatment of gastroin-
testinal, breast, and head and neck cancers [41]. Treat-
ment of colon cancer cell lines with 5-FU induced
ATF3 along with other DNA damage response genes
(GADD34, GADD45a, PCNA) [42].
Overexpression of more than one GADD gene causes
synergistic growth inhibition and/or apoptosis [43].
Therefore the combined induction of GADD45a,
GADD45b and GADD153 by Onconase seen in our
microarray analysis suggests these genes may act syner-
gistically to inhibit MM cell viability.
ORGs very significantly affect MAPK signaling in MM
cells. This is consistent with MAPK regulation of ATF3
[36] as well as the GADD genes [44,45]. Sequential acti-
vation of protein kinases within the MAPK pathways is
a common mechanism of signal transduction in many
Table 2 ORG Signaling Pathways in MM Cells
MAPK Signaling
p = 0.00006
3
Cytokine-Cytokine Receptor
Interaction p = 0.006
Jak-STAT Signaling
p = 0.06
1HSPA1A,
2heat shock 70 KD IL-6, interleukin 6 IL-6, interleukin 6
protein A IL-6ST, interleukin 6 signal IL-6ST, interleukin 6
HSPA1B, heat shock 70 KD transducer signal transducer
protein B CCL2, chemokine (C-C motif) 2 JAK1, janus kinase 1
CACNB3, Ca channel, voltage INHBA, inhibin IL-24, interleukin 24
dependent B3 IL-24, interleukin 24
FGF2, fibroblast growth factor CXCL2, chemokine (C-X-C motif) 2
DUSP6, dual specificity phosphatase 6
JUN, v-jun sarcoma virus homolog
GADD45A, growth arrest DNA damage inducible A
GADD45B, growth arrest DNA damage inducible B
GADD153, DNA damage inducible transcript 3
1Gene symbol, Affymetrix data
2Gene description, Affymetrix data
3p values from [22]
Figure 5 Network of ORGs and signaling pathways in MM cells. Major pathways interacting with ORGs (yellow ovals); select ORGs,
connected to at least two other genes or pathways (blue ovals and lines); select pathway-associated ORGs expressed at least 3-fold over
controls (red ovals). Links between ORGs and major pathways (black lines).
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apoptosis [46]. In fact, MAPK signaling is common to
the action of many divergent chemotherapeutic agents
(reviewed in [47]). In addition to MAPK, AKT signaling
has been shown to influence tumor cell responsiveness
to chemotherapeutics. Although not addressed in this
study, a previous report noted that Onconase induces
apoptosis in MM cells, and that MM cells with the
highest AKT activation were more resistant to the drug
[10].
Recently, genotoxic stress and apoptosis were also
associated with RNA genes [48]. MicroRNAs (miRNAs),
products of non-coding RNA genes, that are transcribed
by RNA polymerase II, are processed and exported to
the cytoplasm where they bind to the 3’ UTRs of target
mRNAs to inhibit translation [49]. Numerous miRNAs
are deregulated in human cancers, consequently affect-
ing their target mRNAs and subsequent protein pro-
ducts [49]. Onconase is known to damage non-coding
RNA (i.e., tRNA) to inhibit protein synthesis, but its
effect on apoptosis has been attributed, at least partly,
to other unknown cellular targets [2], possibly miRNAs
[6]. Interestingly, nine ORGs affect transcription from
the RNA polymerase II promoter, and one of these,
CEBPB, is a target of miRNA-155 [50]. Moreover,
miRNA-155 is up-regulated in some cancers [51], and
its levels are decreased by Onconase in MM cells (K.
Shogen, unpublished data).
Conclusion
Collectively, the results presented here show that a
RNA-damaging drug can impact many of the same
important genes and pathways as standard chemothera-
peutics. Future studies are needed to address whether
ATF3 and IL-24 act as key pro-apoptotic genes to med-
iate the chemotherapeutic response of MM cells to
Onconase. Moreover, it remains to be determined
whether up-regulation of IL-6 and COX-2 expression
could impact the responsiveness of MM patients to
Onconase. Targeting these pro-inflammatory proteins
may lead to improvements in Onconase treatment pro-
tocols. Current findings implicate several new genes in
the response of MM cells to Onconase, and further stu-
dies are expected to elucidate whether up-regulation of
these genes may serve as new biomarkers of response to
Onconase.
Additional file 1: Supplemental Table 1. Table detailing Onconase
regulated gene (ORG) ontologies.
Click here for file
[http://www.biomedcentral.com/content/supplementary/1471-2407-10-
34-S1.PDF]
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